Latest news with #senzime.com
Yahoo
13-05-2025
- Business
- Yahoo
Senzime Launches Medical Affairs Division and Education Platform to Drive Transformation in Anesthesia Monitoring
UPPSALA, Sweden and ST. LOUIS, May 13, 2025 /PRNewswire/ -- Senzime, a global leader in precision-based perioperative monitoring solutions, today announced the formation of a new Medical Affairs division and the parallel launch of Senzime Academy—an open-access education platform designed to advance the implementation of guideline-supported neuromuscular monitoring worldwide. "These initiatives aim to drive the next wave of clinical transformation in anesthesia care, as Senzime continues to strengthen our role not only as a device innovator, but as a scientific and educational partner," said Philip Siberg, CEO of Senzime. "Our new Medical Affairs team and educational platform reflect our commitment to partnering with providers to implement evidence-based practices that elevate patient outcomes." Building a Global Clinical CommunitySenzime's new Medical Affairs division will serve as a hub for collaboration with leading academic centers, anesthesia providers, and perioperative teams. Its mission is to translate clinical research into real-world practice, support best-in-class implementation, and elevate global awareness about the ongoing risks of residual neuromuscular block (rNMB). The division is led by Jen Sanders, Director of Clinical and Medical Affairs. Addressing the Real-World Needs of Anesthesia TeamsTo support widespread adoption of neuromuscular monitoring, Senzime Academy offers clinicians on-demand training on quantitative train-of-four (TOF) monitoring and best practices for TetraGraph® use. The digital platform includes video modules, clinical case examples, and implementation guides for both adult and pediatric care settings. Built on 40+ Years of Scientific ResearchSenzime's flagship TetraGraph system is the result of over four decades of neuromuscular monitoring research, translated into a clinically robust, EMG-based platform purpose-built to meet the demands of modern surgery. Its proprietary TOF monitoring technology is clinically evaluated in 19 peer-reviewed publications, making it the most studied EMG system available today. TetraGraph is used in over 3,500 operating rooms worldwide, supporting compliance with best practices outlined by the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC). More information how Senzime's solutions can be used across specialized clinical applications, such as robotic-assisted surgeries, pediatrics, and enhanced recovery after surgery (ERAS), is available at More information about Senzime Academy is available at For further information, please contact:Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: About SenzimeSenzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at View original content to download multimedia: SOURCE Senzime Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Senzime Publishes Annual and Sustainability Report for 2024
UPPSALA, SWEDEN / / April 24, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) announces today that the company's annual and sustainability report for 2024 is published and available at the website "2024 was a year of high growth, successful product launches, publication of favorable clinical studies, and continued commercial expansion.", commented Philip Siberg, CEO of Senzime For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 15:30 CEST. Attachments Annual Report 2024 SOURCE: Senzime View the original press release on ACCESS Newswire
Yahoo
13-02-2025
- Business
- Yahoo
Invitation to Presentation of Senzime's Fourth Quarter 2024 Report
UPPSALA, SE / / February 13, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime invites investors, analysts, and media to a webcast presentation of the fourth quarter report for 2024 on February 17, 14:00 CET. The report will be published during the morning of the same day. The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&A session moderated by Erik Palin, analyst at Carnegie Investment Bank. The presentation will be held in English. Date and time: Monday, February 17, 14:00 CEST Questions to moderator can be emailed in advance, no later than February 17, 10:00 am CET to: The presentation will be accessible at Senzime's website at For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: Attachments Invitation to presentation of Senzime's fourth quarter 2024 report SOURCE: Senzime View the original press release on ACCESS Newswire Sign in to access your portfolio
